-
$100 Million
Medical Malpractice
Largest-ever compensatory verdict
Read More... -
$153 Million
Then-second largest Product
Liability verdict in U.S. history
Read More... -
$38.2 Million
Delaware County
Auto Accident Verdict
Read More... -
$36.4 Million
Workplace Injury
Largest single-victim fatality settlement
Read More... -
$51 Million
Premises Liability/
Civil Rights verdict
Read More...
- Watch Here For Kline & Specter News Alerts
- Kline & Specter challenges Pa. government/school liability cap
- Kline & Specter Courtroom dedicated at Penn Law School
- Waldenberger wins $3M verdict in cancer case
- On TV ⇒The Kline & Specter Squash Center opens at Drexel University
- On TV ⇒ Specter: state should investigate power lines in Pennsylvania death
- Kline, Caputo win $14M verdict in Pennsbury school bus accident case
- On TV ⇒ Tom Kline interviewed on Penn State case by CNN, MSNBC ...
- Kline & Specter named No. 1 Product Liability Firm in the United States
- Tom Kline delivers keynote address at Bench-Bar convention
- $27.6M verdict upheld in promotional video case
- Specter, Safier, Williams win $17.5M med-mal verdict
- On TV ⇒ Shanin Specter comments on the Ellison case, CBS3
- Guerrini wins $15M verdict in teen's death
- Specter featured on Super Lawyers magazine cover
- Tom Kline again No. 1 in PA, firm has nine named Super Lawyers
- PA Superior Court panel upholds $8.75M Blumer verdict
- Kline & Specter wins largest-ever Erie personal injury verdict, $21.6M
- Michael Smerconish joins Kline & Specter
- On TV ⇒ Kline, Inscho, Baldwin obtain $1.8M in psychologist sex case
- Specter, Jones win $27.6 M verdict vs. medical device, video makers
- Kline & Specter named among Best Law Firms in U.S.
- Trunk, Zakeosian win $11.7 million against PHA and property manager
- Kline, Specter named among nation's 500 "Leading Lawyers"
- On TV ⇒ ESPN features the Plevretes case, Shanin Specter
- Tom Kline named Philadelphia Medical Malpractice Lawyer of the Year
- Best Lawyers names Tom Kline No. 1 Phila. personal injury attorney
- See more Kline & Specter stories in the news
Cancer Lawyer
Pennsylvania - New Jersey - New York - Nationwide

WASHINGTON (Reuters)
NEW YORK | Wed Feb 9, 2011 8:34pm EST
Testicular cancer deaths double with after 40 diagnosis
(Reuters) - Men diagnosed with testicular cancer at 40 years of age or older have twice the risk of dying from the disease as younger patients, according to a study of nearly 28,000 men.
This was true even when initial treatment and the extent of the disease were taken into account, according to findings published in the Journal of Clinical Oncology.
"This study comprehensively documents, for the first time, to our knowledge, the effect of age on TC-specific mortality, while taking into account disease characteristics, treatment factors and socio-demographic variables," wrote Lois Travis, of the University of Rochester Medical Center, New York, along with colleagues from Oslo, Norway.
The research is based on data from the Surveillance, Epidemiology and End Results program, a source for U.S. cancer statistics at the U.S. National Cancer Institute. Travis and her team calculated hazard ratios for 10-year testicular cancer mortality.
Mortality was doubled in patients diagnosed over the age of 40, the study found. But, those diagnosed after 1987 were less likely to die during follow-up than men diagnosed earlier, possibly due to the introduction of a certain kind of chemotherapy about 10 years earlier.
"The question, however, remains whether association between socioeconomic variables and mortality reflect differences in the health care system's ability to offer optimal treatment, the patient's willingness to accept intensive treatment with a non-negligible risk of adverse effects, or the physician's knowledge of optimal treatment approaches," they wrote.
Several factors may account for the age-related mortality difference, including the fact that many older patients are often not treated with the same intensity as younger patients, the researchers said.
The researchers recommended giving more attention to the care of older patients as well as those of people of lower socioeconomic status for the best results.
"In a cancer that is so highly curable, any influence that confers an increased risk of disease-specific mortality must be identified, and interventional strategies adopted," they said.





























